Full Text View
Tabular View
Study Results
Related Studies
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
This study has been completed.
Study NCT01260324   Information provided by Pfizer

First Received on November 5, 2010.   Last Updated on August 17, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Anterior Ischemic Optic Neuropathy
Ischemic Optic Neuropathy
Additional conditions recognized in this trial
Demyelinating Diseases
Ischemia
Nerve Compression Syndromes
Neurologic Manifestations
Neurotoxicity Syndromes
Optic Nerve Diseases
Optic Neuropathy, Ischemic
Polyneuropathies
More general conditions related to this trial
Cardiovascular Diseases
Cranial Nerve Diseases
Eye Diseases
Nervous System Diseases
Neuromuscular Diseases
Pathologic Processes
Peripheral Nervous System Diseases
Poisoning
Signs and Symptoms
Substance-Related Disorders
Vascular Diseases
Additional drug interventions recognized in this trial
Phosphodiesterase 5 Inhibitors
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase Inhibitors
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services